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Background: While microRNA (miRNA) expression is known to be altered in a variety of human malignancies
contributing to cancer development and progression, the potential role of miRNA dysregulation in malignant mast
cell disease has not been previously explored. The purpose of this study was to investigate the potential contribution
of miRNA dysregulation to the biology of canine mast cell tumors (MCTs), a well-established spontaneous model of
malignant mast cell disease.
Methods: We evaluated the miRNA expression profiles from biologically low-grade and biologically high-grade
primary canine MCTs using real-time PCR-based TaqMan Low Density miRNA Arrays and performed real-time PCR to
evaluate miR-9 expression in primary canine MCTs, malignant mast cell lines, and normal bone marrow-derived mast
cells (BMMCs). Mouse mast cell lines and BMMCs were transduced with empty or pre-miR-9 expressing lentiviral
constructs and cell proliferation, caspase 3/7 activity, and invasion were assessed. Transcriptional profiling of cells
overexpressing miR-9 was performed using Affymetrix GeneChip Mouse Gene 2.0 ST arrays and real-time PCR
was performed to validate changes in mRNA expression.
Results: Our data demonstrate that unique miRNA expression profiles correlate with the biological behavior of primary
canine MCTs and that miR-9 expression is increased in biologically high grade canine MCTs and malignant cell lines
compared to biologically low grade tumors and normal canine BMMCs. In transformed mouse malignant mast cell
lines expressing either wild-type (C57) or activating (P815) KIT mutations and mouse BMMCs, miR-9 overexpression
significantly enhanced invasion but had no effect on cell proliferation or apoptosis. Transcriptional profiling of
normal mouse BMMCs and P815 cells possessing enforced miR-9 expression demonstrated dysregulation of several
genes, including upregulation of CMA1, a protease involved in activation of matrix metalloproteases and extracellular
matrix remodeling.
Conclusions: Our findings demonstrate that unique miRNA expression profiles correlate with the biological behavior
of canine MCTs. Furthermore, dysregulation of miR-9 is associated with MCT metastasis potentially through the induction
of an invasive phenotype, identifying a potentially novel pathway for therapeutic intervention.
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Table 1 Primers for quantitative reverse transcriptase
polymerase chain reaction
Primers Primer sequences
Mouse Cma1 292F 5’-GAA GAC ACG TGG CAG AAG CTT GAG-3’
Mouse Cma1 521R 5’-GTG TCG GAG GCT GGC TCA TTC ACG-3’
Mouse Hspe F479 5’-GCT CAG TGG ACA TGC TCT ACA G-3’
Mouse Hspe R697 5’-GCA ACC CAT CGA TGA GAA TGT G-3’
Mouse Ifitm3 115F 5’-GCT TCT GTC AGA ACT ACT GTG-3’
Mouse Ifitm3 339R 5’-GAG GAC CAA GGT GCT GAT GTT CAG-3’
Mouse Mlana 125F 5’-GCT GCT GGT ACT GTA GAA GAC G-3’
Mouse Mlana 322R 5’-GTG AAG AGA GCT TCT CAT AGG CAG-3’
Mouse Pdzk1ip1 F520 5’-GTT CTG GCT GAT GAT CAC TTG ATT G-3’
Mouse Pdzk1ip1 R769 5’-GAT AGA AGC CAT AGC CAT TGC TG-3’
Mouse SerpinF1 712F 5’-GTG AGA GTC CCC ATG ATG TCA G-3’
Mouse SerpinF1 910R 5’-GTT CTC GGT CGA TGT CAT GAA TG-3’
Mouse Tlr7 F2284 5’-GTC ATT CAG AAG ACT AGC TTC CCA G-3’
Mouse Tlr7 R2441 5’-GTC ACA TCA GTG GCC AGG TAT G-3’
Mouse Cd200r1 659F 5’-GTA ACC AAT CTC TGT CCA TAG-3’
Mouse Cd200r1 902R 5’-GTC ACA GTA TCA TAG AGT GGA TTG-3’
Mouse Cd200r4 312F 5’-GCC TCC ACA CCT GAC CAC AG-3’
Mouse Cd200r4 532R 5’-GTC CAA GAG ATC TGT GCA GCA G-3’
Mouse Perp F108 5’-GCA GTC TAG CAA CCA CAT CCA G-3’
Mouse Perp R267 5’-GCA CAG GAT GAT AAA GCC ACA G-3’
Mouse Slpi F142 5’-GAG AAG CCA CAA TGC CGT ACT G-3’
Mouse Slpi R378 5’-GAC TTT CCC ACA TAT ACC CTC ACA G-3’
Mouse Pparg F682 5’-GAT ATC GAC CAG CTG AAC CCA G-3’
Mouse Pparg R983 5’-GCA TAC TCT GTG ATC TCT TGC ACG-3’
18S V2F 5’-AAA TCC TTT AAC GAG GAT CCA TT-3’
18S V2R 5’-AAT ATA CGC TAT TGG AGC TGG A-3’
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Mast cell-associated malignancies are important diseases
in both humans and dogs [1,2] and are characterized by
activating mutations in KIT in both species. More than
90% of human patients with systemic mastocytosis carry
the D816V mutation in KIT [3] which results in consti-
tutive activation of KIT signaling and plays a major role
in the proliferative phenotype. A functionally identical
mutation (D814V) is found in transformed mast cell
lines from rodents [4,5]. Similarly, approximately 30%
of dogs with high-grade cutaneous mast cell tumors
(MCTs) possess activating internal tandem duplications
(ITDs) in the KIT juxtamembrane (JM) domain [6,7].
More recently, activating mutations in the extracellular
domain of KIT (exons 8 and 9) have also been identified
in a proportion of canine MCTs [8]. While the role of
KIT dysfunction in mast cell neoplasia has been well
described, little is known regarding additional molecular
mechanisms that may contribute to invasion and metas-
tasis of malignant mast cells.
The expression of matrix metalloproteinases (MMPs),
a family of enzymes involved in the degradation and
remodeling of extracellular matrix, has been implicated
in the neoplastic transformation of mast cells. Normal
canine bone marrow-derived mast cells (BMMCs) pro-
duce large quantities of inactive and active MMP9 in re-
sponse to various stimuli while releasing little detectable
MMP2 [9]. Neoplastic mast cells are known to produce
both MMP2 and MMP9 [10] suggesting that the ability
to produce MMP2 may be a feature acquired by malig-
nant mast cells. Furthermore, high-grade MCTs express
significantly higher levels of MMP9 in proactive and ac-
tive forms, which has been proposed to be associated
with the high degree of malignant behavior of these
tumors [10,11]. More recently, characterization of the
proteome of primary canine low-grade MCTs and aggres-
sive, high-grade MCTs identified differentially expressed
proteins between the two groups [12]. Several stress re-
sponse proteins (HSPA9, TCP1A, TCP1E) and cytoskeletal
proteins associated with actin remodeling and cell migra-
tion (WDR1) were significantly up-regulated in high-grade
MCTs.
MicroRNAs (miRNAs) are highly conserved, noncod-
ing RNAs that serve as important regulators of gene
expression. It is well established that miRNA expression
is altered in many human malignancies and that miRNAs
function as tumor suppressor genes or oncogenes through
dysregulation of target genes [13]. Currently there is
limited information regarding the potential role of
miRNA dysregulation in malignant mast cell disease.
Several miRNAs appear to play an important role in nor-
mal murine mast cell differentiation [14] and following
activation of murine mast cells, up-regulation of the
miR-221-222 family influences cell-cycle checkpoints, inpart by targeting p27Kip1 [15]. Basal levels of miR-221 con-
tribute to the regulation of the cell cycle in resting mast
cells. However, its effects are activation-dependent and in
response to mast cell stimulation; miR-221 regulates de-
granulation, cytokine production, and cell adherence [16].
More recent studies have demonstrated roles for miR-539
and miR-381 in mediating a novel regulatory pathway be-
tween KIT and microphthalmia-associated transcription
factor in normal and malignant mast cells [17].
The purpose of this study was to investigate the poten-
tial role of miRNA dysregulation in the biologic behavior
of primary canine MCTs. We found that unique miRNA
expression profiles correlate with the biological behavior of
primary canine MCTs and that miR-9 was significantly
overexpressed in aggressive MCTs compared to benign
MCTs. Furthermore, enforced miR-9 expression in murine
mastocytoma cell lines and normal murine BMMCs with
low basal levels of miR-9 enhanced invasion and induced
the expression of several target genes associated with
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(HSPE). These data suggest that miR-9 overexpression may
contribute to the invasive phenotype of malignant mast
cells thereby providing a potentially novel pathway for
therapeutic intervention in malignant mast cell disease.
Methods
Cell lines, primary cell cultures, primary tumor samples
Mouse P815 (D814V KIT mutation) and C57 (wild-type
KIT) cell lines were provided by Dr. Stephen Galli
(Stanford University). The canine BR (activating point
mutation L575P in the JM domain of KIT) and C2 (KIT
ITD mutation in the JM domain) cell lines were provided
by Dr. Warren Gold (Cardiovascular Research Institute,
University of California- San Francisco). Cell lines were
maintained in RPMI 1640 (Gibco® Life Technologies,
Grand Island, NY, USA) supplemented with 10% fetal
bovine serum (Gibco® Life Technologies) and antibiotics
(Gibco® Life Technologies). Mouse BMMCs were gener-
ated from bone marrow from C57/B6 wild-type mice as
previously described [9]. Canine BMMCs were gener-
ated from 2 dogs and maintained in Stemline (Sigma-
Aldrich, St. Louis, MO, USA) medium supplemented with
recombinant canine stem cell factor (R & D Systems,
Minneapolis, MN, USA) as previously described [18]. Pro-
tocols for collection of murine bone marrow and canine
bone marrow were approved by the Ohio State UniversityFigure 1 MiRNA expression in primary canine MCTs is associated with
diagnosed with benign tumors (n = 12) or biologically high grade metastati
Biosystems Human TaqMan Low Density miRNA Arrays to assess mature m
analysis separated samples into two groups based on biological behavior
biologically low-grade (L) tumors or high-grade (H) tumors (P < 0.05). (*) in
tumor that clustered with the biologically high grade MCT group.(OSU) Institutional Care and Use Committee (IACUC),
protocols 2009A0204 and 2010A0015, respectively. Ca-
nine MCTs were obtained from 24 different affected dogs
presented to the OSU Veterinary Medical Center and
University of California-Davis (UCD) Veterinary Teaching
Hospital. Tumor sample collections were performed in ac-
cordance with established hospital protocols and approved
by respective IACUC at both OSU and UCD. Clinical out-
come data, including sex, breed, primary tumor location,
recurrence and metastasis, histopathologic grade, mitotic
index, and outcome was available for all dogs (see
Additional file 1). Tumors obtained from dogs that were
adequately controlled with surgery alone and did not de-
velop or die from metastatic mast cell disease were con-
sidered biologically low-grade tumors (benign). Tumors
from dogs that developed aggressive, metastatic mast cell
disease which resulted in their death were classified as
biologically high-grade tumors.
Quantitative reverse-transcription-PCR profiling of mature
miRNA expression in MCT biopsies
Total RNA was isolated by the Trizol method (Invitrogen,
Carlsbad, CA, USA) and heparinase treated as described
[19]. Primary MCT miRNA expression profiling was per-
formed at the OSU Nucleic Acid Shared Resource using
the TaqMan Array Human miRNA Panel (Human A
Cards, v.2, Applied Biosystems, Foster City, CA, USA) asbiological behavior. Primary canine MCTs were obtained from dogs
c tumors (n = 12). Real-time PCR profiling was performed using Applied
iRNA expression in primary tumors. Unsupervised hierarchical cluster
and demonstrate unique miRNA expression profiles associated with
dicates primary tumor sample from a dog with a benign mast cell
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of 377 human miRNAs, 151 of whose mature sequences
are 100% conserved between human and dog (Sanger
miRBase v.12). Raw data analysis, normalizer selection
and statistical analysis were performed using the real-time
PCR analysis software Statminer (Integromics, Madison,
WI, USA). The snRNA U6 was confirmed to be stably
expressed in our sample set and the mean used as the
normalizer value. Relative gene expression was calculated
using the comparative threshold cycle method [21]. Gene
expression heat maps were generated using Treeview PC-
based software [22].
RNA isolation and quantitative real-time PCR
RNA was extracted from cell lines using TRIzol
(Invitrogen) and real-time PCR was performed using theTable 2 MiRNA signature associated with biologically high-gr
miRNA Fold-change p-value
Gene expression



























hsa-miR-372 2.4 0.019Applied Biosystems StepOne Plus Detection System.
MiR-9 is highly conserved and shares 100% homology be-
tween dogs, humans, and mice. Mature miR-9 expression
was performed using Taqman miRNA assays (Applied
Biosystems). 50 ng total RNA was converted to first-
strand cDNA with miRNA-specific primers, followed by
real-time PCR with TaqMan probes. All samples were nor-
malized to U6 snRNA.
Real-time PCR was performed to validate changes in
mRNA expression for selected genes affected by miR-9
over expression. cDNA was made from 1 μg of total
RNA using Superscript III (Invitrogen). CMA1, HSPE,
IFITM3, MLANA, PERP, PPARG, PDZK1IP1, SERPINF1,
SLPI, TLR7, CD200R1, CD200R4 and 18S transcripts
were detected using Fast SYBR green PCR master mix
(Applied Biosystems) according to the manufacturer’sade MCTs
miRNA Fold-change p-value
Gene expression
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malization was performed relative to 18S rRNA. All
reactions were performed in triplicate and included no-
template controls for each gene. Relative gene expression
for all real-time PCR data was calculated using the com-
parative threshold cycle method [21]. Experiments were
repeated 3 times using samples in triplicate.
MiR-9 lentivirus infection
Lentiviral constructs were purchased from Systems
Biosciences (Mountain View, CA, USA). Packaging of the
lentiviral constructs was performed using the pPACKH1
Lentivector Packaging KIT (catalog no. LV500A-1) ac-
cording to the manufacturer’s instructions. P815 and
C57 mouse mastocytoma cells and mouse BMMCs
(105 cells) were transduced with empty lentivirus (catalog
no. CD511B-1) or pre-miR-9-3 lentivirus (catalog no.
PMIRH9-3PA-1). FACS-mediated cell sorting based on
GFP expression was performed 72 hours post-transduction
and miR-9 expression was evaluated by real-time PCR
(Applied Biosystems).
Transcriptional profiling of cells transduced with miR-9
lentivirus
RNA was extracted from mouse BMMCs and P815 cells
transduced with empty lentivirus or pre-miR-9-3 lenti-
virus from three separate transduction experiments
using TRIzol (Invitrogen). A secondary RNA cleanup
step was performed using QIAGEN RNeasy Total RNA
isolation kit (QIAGEN GmbH, Hilden, Germany) and
RNA integrity was assessed using RNA 6000 Nano
LabChip® Kits on the Agilent Bioanalyzer 2100 (Agilent




























Low Grade MCTs High Grade MCTs 
A
Figure 2 MiR-9 is highly expressed in biologically high grade canine M
mature miR-9 expression in primary canine MCTs demonstrated that the m
MCTs compared to benign MCTs (p = 0.001). (*) indicates primary tumor sa
levels of miR-9 but had lymph node metastasis at the time of surgery. (B) M
BMMCs, and malignant mouse C57 and P815 cells were cultured and re
independent experiments were performed and all reactions were performed
twice for normal cBMMCs.with Cy3 using RNA ligase and hybridized to GeneChip®
Mouse Gene 2.0 ST Arrays (Affymetrix, Santa Clara,
CA, USA). Ratios of signals were calculated and tran-
scripts that were up-regulated or down-regulated by
at least 2-fold were identified (p < 0.05). Data analysis,
statistical analysis, and generation of gene expression heat
maps were performed using Affymetrix® Transcriptome
Analysis Console (TAC) Software. Prediction of miR-9
binding to the 3’-UTR of genes down-regulated by miR-9
was performed with computer-aided algorithms ob-
tained from TargetScan (http://www.targetscan.org), PicTar
(http://pictar.mdc-berlin.de), miRanda (http://www.micro-
rna.org), and miRWalk (http://www.umm.uni-heidelberg.
de/apps/zmf/mirwalk).
Matrigel invasion assay
To assess the effect of miR-9 expression on invasion, cell
culture inserts (8-μm pore size; Falcon) were coated with
100 μL of Matrigel (BD Bioscience, San Jose, CA, USA)
to form a thin continuous layer and allowed to solidify
at 37°C for 1 hour. P815 and C57 cell lines, and mouse
BMMCs (5 × 105/mL) transduced with control lentivirus
or pre-miR-9-3 lentivirus were prepared in serum-free
medium and seeded into each insert (upper chamber)
and media containing 10% fetal bovine serum was placed
in the lower chamber. The cells were incubated for
24 hours to permit invasion through the Matrigel layer.
Cells remaining on the upper surface of the insert mem-
brane were wiped away using a cotton swab, and cells
that had migrated to the lower surface were stained with
crystal violet and counted in ten independent 20× high
powered fields for each sample. Experiments were re-


























cBMMC BR C2 mBMMC P815 C57 
B
CTs and malignant mast cell lines. (A) Real-time PCR evaluating
ean expression of miR-9 was 3.2-fold higher in aggressive, high grade
mple from a dog with a low-grade mast cell tumor that expressed high
alignant canine BR and C2 mast cells, normal canine and mouse
al-time PCR was performed to assess miR-9 expression levels. Three
in triplicate. The experiments were repeated 3 times in the cell lines and
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Changes in cell proliferation were assessed using the
CyQUANT® Cell Proliferation Assay KIT (Molecular
Probes, Eugene, OR, USA) as previously described [23].
P815 and C57 cells (15 × 104) transduced with control
lentivirus or pre-miR-9-3 lentivirus were seeded in 96-well
plates for 24, 48, and 72 hours prior to analysis. Nontrans-
duced P815 and C57 cells served as negative control
wells. Fluorescence was measured using a SpectraMax mi-
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C57 (WT KIT) 
C57 (WT KIT) 
P815 (D814V) KIT) 





















































Figure 3 Overexpression of miR-9 enhances invasion of malignant ma
(A) Mouse P815 and C57 mast cells transduced with pre-miR-9-3 lentivirus
on GFP expression. MiR-9 levels were assessed by real-time PCR in wild-type, e
experiments were performed and all reactions were performed in triplicate. (B
pre-miR-9-3 lentivirus were transferred onto cell culture inserts coated with M
that had invaded the membrane were counted in ten independent 20x hpf f
assays were performed in triplicate wells (*p < 0.05). (C) Mouse P185 and C5
lentivirus vector and cell proliferation was analyzed at 24, 48, and 72 hours
as non-treated controls. Three independent experiments were performed an
percentage of untransduced control cells. (D) Mouse P185 and C57 mast ce
assessed for apoptosis at 24 and 48 hours by measuring active caspase-3/7 us
fluorescence units are reported after subtraction of fluorescence levels of wellCell proliferation was calculated as a percentage of
untransduced control cells.
Caspase-3/7 activity was determined using the Senso-
Lyte® Homogeneous AMC Caspase- 3/7 Assay KIT
(Anaspec Inc, San Jose, CA, USA) as previously de-
scribed [24]. P815 and C57 cells (5.0 × 104) transduced
with either empty lentivirus or pre-miR-9-3 lentivirus
were plated for 24 and 48 hours in 96-well plates prior
to analysis. Fluorescence was measured on a SpectraMax
microplate reader (Molecular Devices). Levels of caspase* *
WT EV miR-9 WT EV miR-9
C57 (WT KIT) 
C57 (WT KIT) 
P815 (D814V) KIT) 













































































st cells and has no effect on cell proliferation or apoptosis.
or empty vector control were sorted to greater than 95% purity based
mpty vector, and miR-9 expressing cells (*p < 0.05). Three independent
) Mouse P185 and C57 mast cells transduced with either empty vector or
atrigel® for 24 hrs. After incubation, membranes were stained and cells
or each sample. Three independent experiments were performed and all
7 mast cells were transduced with either empty vector or pre-miR-9-3
using the CyQUANT method. Nontransduced P815 and C57 cells served
d all samples were seeded in triplicate wells. Values are reported as
lls transduced with either empty vector or pre-miR-9-3 lentivirus were
ing the SensoLyte® Homogeneous AMC Caspase-3/7 Assay kit. Relative
s with medium only.
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cence levels of wells with medium only.
Statistical analysis
Statistical analysis relative to miRNA expression data
was performed with Statminer software (Integromics)
and p-values of <0.05 were considered statistically sig-
nificant. Statistical analysis relative to mRNA expression
data was performed using Affymetrix® Transcriptome
Analysis Console (TAC) Software. Differential gene
expression was determined by one-way ANOVA com-
parison test and p-values of <0.05 were considered sta-
tistically significant. All experiments with the exception
of those involving canine BMMCs were performed in
triplicate and repeated 3 times. Experiments using canine
BMMCs were performed in triplicate, but repeated only
twice because of limited cell numbers. Data were presented
as mean plus or minus standard deviation. The difference
between two group means was analyzed using the Students
t-test and a one-way analysis of variance (ANOVA) was
performed for multiple variable comparisons. P-values
of <0.05 were considered significant.
Results
MiRNA expression in primary canine MCTs is associated
with biological behavior
To investigate the role of miRNA dysregulation in the
biologic behavior of mast cell disease, global miRNA ex-






























Figure 4 Overexpression of miR-9 enhances invasion in normal mous
with pre-miR-9-3 lentivirus or empty vector control were sorted to greater
by real-time PCR (*p < 0.05). Three independent experiments were performed
with either empty vector or pre-miR-9-3 lentivirus were transferred onto cell c
remaining on the upper surface of the insert membrane were wiped away us
stained with crystal violet and counted in ten independent 20x hpf for each s
were performed in triplicate wells (*p < 0.05).diagnosed with benign tumors (n = 12) or with biologic-
ally high-grade tumors (n = 12) was evaluated using real-
time PCR-based TaqMan Low Density miRNA Arrays
(Applied Biosystems). An unsupervised hierarchial clus-
ter analysis of all primary MCTs readily separated tu-
mors into groups based on biological behavior with
aggressive, highly metastatic MCTs clustering together
and clinically benign MCTs clustering together separ-
ately (Figure 1). We identified 45 miRNAs that had
significantly higher expression in biologically high-
grade MCTs compared to biologically low-grade MCTs,
while 7 miRNAs had lower expression (Table 2). These
data demonstrate that biologically high-grade and low-
grade canine MCTs possess distinct miRNA expression
signatures.
miR-9 is overexpressed in biologically high-grade
canine MCTs
The miRNA array performed above identified miR-9 as
overexpressed in MCTs that metastasized and resulted
in death of affected dogs. This finding was confirmed by
real-time PCR in which a 3.2-fold increase in miR-9 ex-
pression was identified in biologically aggressive MCTs
as compared to benign MCTs (Figure 2A). Furthermore,
miR-9 expression correlates with tumor grade and meta-
static status in human breast cancer, providing further
support for the idea that altered miR-9 expression may
be an important regulator of aggressive biological behavior


























e bone marrow-derived mast cells. (A) Normal mBMMCs transduced
than 95% purity based on GFP expression. MiR-9 levels were assessed
and all reactions were performed in triplicate. (B) mBMMCs transduced
ulture inserts coated with Matrigel® for 24 hrs. After incubation, cells
ing a cotton swab, and cells that had migrated to the lower surface were












Figure 5 (See legend on next page.)
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(See figure on previous page.)
Figure 5 Overexpression of miR-9 in normal mouse bone marrow-derived mast cells significantly alters gene expression. Normal
mBMMCs transduced with pre-miR-9-3 lentivirus or empty vector control were sorted based on GFP expression. RNA was harvested from mouse
BMMCs transduced with empty vector or pre-miR-9-3 lentivirus from three separate transduction experiments. Transcriptional profiling was
performed using Affymetrix GeneChip® Mouse Gene 2.0 ST Arrays. Hierarchical clustering was performed for 450 genes differentially expressed
(p < 0.05) in mBMMCs expressing either empty vector (EV) or miR-9 (miR9) as determined by one-way ANOVA comparison test (p < 0.05). Mean
centered signal intensities of gene-expression are depicted by the log2 of the ratio of the signals against the average signal for each comparison.
Color areas indicate relative expression of each gene after log2 transformation with respect to the gene median expression (red above, green
below, and black equal to the mean).
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grade MCT expressed high levels of miR-9 and the
unsupervised hierarchial clustering of all 24 MCTs
demonstrated that this dog’s tumor clustered with the
biologically high-grade tumors (Figure 1). Clinical data
was subsequently reviewed for all dogs and it was de-
termined that this dog had histopathologically con-
firmed evidence of metastatic mast cells present in a
regional lymph node surgically excised at the time of
primary tumor removal. Additionally, one high-grade
MCT clustered with the low-grade tumors, however, this
may have been due, in part, to variations in stroma/
inflammatory cells within the primary tumor specimen
or baseline necrosis within the tumor that influenced the
proportion of tumor cells. Taken together, these findings
suggest a correlation between miR-9 expression levels in
primary canine MCTs and metastatic behavior.
miR-9 expression is up-regulated in canine malignant
mast cell lines
Given the potential link between miR-9 expression and
biological behavior of MCTs, we next evaluated miR-9
expression in canine (BR and C2) and murine (C57 and
P815) mast cell lines and normal canine and murine
BMMCs by real-time PCR. As shown in Figure 2B,
canine mastocytoma cells exhibited higher levels of
miR-9 expression when compared with normal canine
BMMCs. In contrast, both mouse C57 and P815 cells
and mouse BMMCs demonstrated low basal levels of
miR-9. The mouse P815 mastocytoma cell line is a
leukemia of mast cell origin, whereas the canine BR
and C2 mastocytoma cells are derived from cutaneous
tumors. The differences in the biology of these diseases
may account for the observed differences in miR-9
expression in canine and murine cell lines. Low miR-9
expression in P815 cells may reflect the fact that these
cells represent a true leukemia, in contrast to the BR
and C2 cell lines which are derived from cutaneous tu-
mors that would metastasize via the lymphatic system.
Given prior work from our laboratory showing that the
C2 line exhibits invasive behavior in vitro while the
P815 line does not [24], it was possible that miR-9
expression was associated with the invasive behavior of
mast cells.Overexpression of pre-miR-9 enhances invasion of
malignant mast cell lines
To investigate the functional consequences of miR-9
overexpression in malignant mast cell lines, we stably
expressed miR-9 in the mouse P815 and C57 cell lines
that exhibit low basal levels of this miRNA using an
empty or pre-miR-9-3 expressing lentivirus vector. Fol-
lowing transduction, GFP + cells were sorted and miR-9
expression was confirmed by real-time PCR (Figure 3A).
The invasive capacity of cells was then evaluated using
a standard Matrigel invasion assay after 24 hours of
culture. As shown in Figure 3B, enforced expression
of miR-9 in C57 and P815 mast cell lines significantly
enhanced their invasion compared to cells expressing
empty vector.
miR-9 has no effect on cell proliferation or caspase-3,7
dependent apoptosis in malignant mast cells
To investigate whether overexpression of miR-9 in ma-
lignant mast cells affected their capacity to proliferate or
survive, mouse C57 and P815 cell lines expressing pre-
miR-9-3 lentivirus or empty vector control were cultured
for 24, 48, and 72 hrs and the impact on cell prolifera-
tion and apoptosis was assessed. No effects of miR-9 on
proliferation or apoptosis were observed in either cell
line when compared to cells expressing empty vector
(Figure 3C and D).
miR-9 expression enhances invasion in normal
mouse BMMCs
To characterize the biological consequences of miR-9
overexpression in normal mast cells, we transduced
murine BMMCs with pre-miR-9-3 lentivirus or empty
control vector. MiR-9 overexpression in transformed
BMMCs was confirmed by quantitative real-time PCR
(Figure 4A). To assess the effect of ectopic miR-9
expression on the invasive capacity the BMMCs, a
Matrigel invasion assay was again performed. Consistent
with findings in the P815 and C57 cell lines, enforced
expression of miR-9 in mouse BMMCs significantly
enhanced their invasive capacity compared to cells ex-
pressing empty vector (Figure 4B). Together, these data
suggest that miR-9 promotes an invasive phenotype in
mast cells.
Table 3 Gene transcripts altered by miR-9 overexpression
in BMMCs








































Dennd2d, 2010016I18Rik Pdlim1 Ube2e2
Dnajc6 Perp Vmn1r129
Ear2, Ear12, Ear3 Pga5 Zbtb10
Egln3 Phf10 Zfp608
Bold indicates predicted miR-9 targets.
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To gain insight into possible mechanisms underlying the
observed miR-9-dependent invasive behavior of mast
cells, we compared the transcriptional profiles of murine
BMMCs overexpressing miR-9 to those expressing empty
vector and found marked changes in gene expression
(Figure 5). In BMMCs overexpressing miR-9, 321 tran-
scripts were significantly up-regulated (>2-fold) and 129
transcripts were significantly down-regulated (Table 3,
Table 4). Bioinformatic analysis identified putative miR-9
target sites within the 3’-UTR of 40 gene transcripts that
were significantly down-regulated with miR-9 overex-
pression, suggesting that miR-9 may directly target and
regulate expression of these candidate genes (Table 3,
bolded). Real time PCR confirmed that one of these genes,
peroxisome proliferator-activated receptor δ (PPARG) was
down-regulated, a finding consistent with recent studies
demonstrating regulation of PPARG by miR-9 through dir-
ect targeting of its 3’-UTR [25]. We performed real-time
PCR to validate changes in gene expression for several
transcripts altered by miR-9 overexpression in BMMCs.
Consistent with our microarray results, we found that tran-
scripts for HSPE and TLR7 were significantly up-regulated
in BMMCs expressing miR-9, whereas transcripts for
PPARG, PERP, and SLPI were significantly down-regulated
compared to empty vector controls (Figure 6A).
Similar transcriptional profile analysis was performed
using malignant mouse P815 cells and we identified 46
transcripts significantly up-regulated (>2-fold) and 48
transcripts significantly down-regulated in the miR-9 ex-
pressing P815 cells (Table 5). Bioinformatic analysis
identified putative miR-9 target sites within the 3’-UTR
of 15 gene transcripts that were significantly down-
regulated following miR-9 overexpression, suggesting
that miR-9 may directly regulate these genes (Table 5,
bolded). Real-time PCR demonstrated that expression of
SERPINF1 and MLANA transcript was up-regulated in
P815 cells overexpressing miR-9, whereas CD200R1 and
CD200R4 was down-regulated compared to empty vec-
tor controls (Figure 6B).
A comparison of the transcriptional profiles both from
normal BMMCs and malignant P815 cells overexpressing
miR-9 found that most gene transcripts altered by miR-9
were specific to normal or malignant mast cells. We identi-
fied 7 gene transcripts (IFITM3, PDZK1IP1, CMA1,
MGL1, TMEM223, SLAMF1, CLEC4E) that showed simi-
lar changes in expression following miR-9 overexpression
in both BMMCs and P815 cells. We performed real-time
PCR to validate changes in gene expression for several tran-
scripts altered by miR-9 overexpression, including mast
cell chymase (CMA1), interferon-induced transmem-
brane protein 3 (IFITM3), and PDZK1 interacting protein
1 (PDZK1IP1). Consistent with our microarray results,
real-time PCR confirmed that enforced miR-9 expression
Table 4 Gene transcripts altered by miR-9 overexpression
in BMMCs
Upregulated with miR-9 expression (BMMCs)
1810011H11Rik Ddx60 Irg1 Plxna1
2310028H24Rik Dnaja4 Itgb5 Plxnb3
3110043O21Rik Dpep2 Kcnab3 Plxnc1
4930420K17Rik Dusp22 Kcne3 Ppargc1a
5033411D12Rik E130215H24Rik Kctd12 Ppfibp2




9030625A04Rik Egr1 Kit Prickle1
9430070O13Rik Emx2 Klf2 Psd3
9930111J21Rik2 Epsti1 Klk1b1 Psg23
A130040M12Rik Esco2 Klk1b11 Ptafr
A230098N10Rik Esr1 Klk1b27 Ptger2
A430084P05Rik Evl Klk1b5 Ptplad2
A4galt F13a1 Kmo Ptpn13
Abi3 Fabp5 Lce6a Qpct
Adamtsl3 Fabp5, Gm3601 LOC100038947 Rasgrp3
Adrb2 Fam125b LOC100861753 Rassf4
AI593442 Fam55d LOC100861977 Rbm47
AI607873 Fam69a LOC100862646 Rin2
Alcam Fcgr4 Lphn1 Rnase4, Ang
Alpk2 Fkbp1b Lrp1 Rnase6
Ank Fos Lrrc16a Rnf180
Ano3 Fpr2 Lrrc25 Rny1
Aoah Galnt10 Lrrtm1 Rps6ka2
Apobec1 Galntl4 Ltf Rsph9
Ar Gas6 Ly6i Rtp4
Arhgap20 Gbp3 Lyz1 Ryr3
Arhgap24 Gbp4 Maf Scn1b
Arhgap31 Gbp5 Mast4 Scpep1
Arl5b Gbp8 Mc1r Serpinb8
Asphd2 Gbp9 Mecom Siglec1
Bank1 Gcet2 Mgl2 Sirpb1a
BC013712 Gdf15 Mgll Sirpb1b
Bcl2a1b, Bcl2a1a Gdpd1 Mir15b Slc30a2
Bcl2a1d, Bcl2a1a,
Bcl2a1b Ggh Mir181a-1 Slc37a2




Bst1 Gm12250 Mir511 Slc4a11
Bst2 Gm14446 Mir701 Slc6a12
C1qb Gm15915 Mlph Slc9a9
C1qc Gm1673 Mmp2 Slfn5
Table 4 Gene transcripts altered by miR-9 overexpression
in BMMCs (Continued)
C330018A13Rik Gm1966 Mnda, Ifi204 Smpdl3b




Cadm3 Gm4951 Mrgprb2 St3gal5
Car8 Gm5431 Ms4a4a St6galnac3
Ccl2 Gm7977 Ms4a6b Stab1
Ccl4 Gmpr Ms4a6c Stfa3
Ccl7 Gna14 Ms4a6d Sult1a1
Ccnd1 Gp1ba Ms4a7 Syn2
Ccr1l1 Gp5 Msr1 Syngr1
Ccr3 Gpm6a Mtss1 Tdrd5
Ccr5 Gpr55 Nav1 Tek
Ccrl2 Grap2 Neb Tgfbr2
Cd14 H2-DMa Nlrp1b Tlr1




Cd28 Hey2 Nrn1 Tlr9
Cd300a Hist1h1d Oas2 Tmem106a
Cd300lb Hist1h1e Oasl2 Tmem233
Cd300ld Hist1h2bg Olfr1033 Tmem86a
Cd86 Hist2h3b Olfr110 Tnfrsf1b
Cdh2 Hist2h4 Olfr111 Tns1
Chst15, Gm10584 Hist3h2a Olfr1392 Trem1
Cited4 Hist4h4 Olfr1393 Trim30c
Clec4a1 Hivep2 Olfr915 Trim30d
Clec4d Hpse Olfr916 Trim58
Clec4n Hsd3b6 Olfr917 Trpc6
Cma1 Ier2 Olfr918 Tsc22d3
Cma2 Ifi204 Orm3 Tspan13
Cmklr1 Ifi27l2a, Ifi27l2b P2rx7 Tspan8
Creb5 Ifitm3 P2ry6 Tubb2b
Csf1r Ifitm6 Pcdhga10 Txk
Ctnna2 Ighm Pcdhgb6 Ugt1a10
Ctsh Igk-V28 Pdzk1ip1 Unc93b1
Cx3cr1 Il18 Pgap1 Zbp1
Cybb Il2ra Pid1 Zbtb8a
Cyp4a12a Il6ra Pion Zfhx3
Dab2 Iqsec3 Pld2
Darc Irf5, Tnpo3 Pld4
Dbc1 Irf8 Plekhm3
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Figure 6 Identification of transcripts dysregulated by miR-9 overexpression in normal murine BMMCs and P815 malignant mast cells.
(A) Transcriptional profiling of mBMMCs expressing pre-miR-9-3 lentivirus or empty vector control was performed using Affymetrix GeneChip®
Mouse Gene 2.0 ST Arrays to identify genes showing differential expression (>2-fold) with miR-9 overexpression. Real-time PCR was performed
to validate changes in gene expression for transcripts (HSPE, TLR7, PERP, PPARG, SLPI) altered by miR-9 overexpression in mBMMCs (*p < 0.05).
(B) Transcriptional profiling of P815 mast cells expressing pre-miR-9-3 lentivirus or empty vector control was performed as described above. Real-time
PCR was performed to independently validate expression levels of genes (SERPINF1, MLANA, CD200R1, CD200R4) altered by enforced miR-9 expression
in P815 cells (*p < 0.05). (C) Mouse BMMCs and P815 cells expressing pre-miR-9-3 lentivirus or empty vector control were collected and real-time PCR
for IFITM3, PDZK1IP1, and CMA1 was performed (*p < 0.05). Three independent experiments were performed using cells from 3 separate transduction
experiments and all reactions were performed in triplicate.
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http://www.biomedcentral.com/1471-2407/14/84significantly upregulated CMA1, IFITM3, and PDZK1IP1
transcripts in mouse BMMCs and P815 cells (Figure 6C).
These findings provide further support for the notion that
miR-9 induces alterations in gene expression that may
contribute to the development of an invasive phenotype.
Discussion
MiRNAs regulate various biological functions in normal
cells such as growth and differentiation, and they areincreasingly recognized as playing critical roles in cancer
development and progression. Dysregulation of miRNA
expression resulting from amplification or loss of miRNAs
in tumors compared to their normal tissue counterparts
suggests that miRNAs can function as either oncogenes or
tumor suppressor genes [13]. Studies evaluating miRNA
expression in spontaneously occurring tumors in dogs
demonstrate that similar to human cancers, alteration of
miRNAs likely contributes to tumorigenesis and that high-
Table 5 Gene transcripts altered by miR-9 overexpression
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http://www.biomedcentral.com/1471-2407/14/84throughput methodologies used for the study of miRNAs
in human tissues can also be applied to dogs [26-32].
Cutaneous MCTs are the most common skin tumor in
dogs; however, little is known regarding mechanisms
underlying malignant transformation of these cells. The
biological behavior of canine MCTs ranges from rela-
tively benign disease cured with surgical removal to ag-
gressive, highly metastatic tumors ultimately resulting
in the death of affected dogs. While the presence of acti-
vating KIT mutations helps to explain the behavior
of some canine MCTs, little is known regarding the
potential role of miRNAs in both normal and malig-
nant mast cells. The purpose of this study was to begin
to investigate the potential role of miRNA dysregulation
in canine MCTs that exhibit aggressive biologic behavior.
MiRNA expression profiling of primary canine MCTs
identified unique miRNA signatures associated with ag-
gressive MCTs as compared to benign MCTs. The un-
supervised hierarchical clustering of primary cutaneous
MCTs based on their miRNA expression profiles recapit-
ulated the grouping of the tumors based on their bio-
logical behavior, supporting the notion that miRNA
dysregulation is associated with the biologic behavior of
canine MCTs. Furthermore, we found that miR-9 expres-
sion was significantly upregulated in aggressive MCTs
compared to benign MCTs. Interestingly, miR-9 was iden-
tified as a pro-metastatic miRNA in human breast cancer
cell lines through its ability to enhance cell motility and
invasiveness in vitro and metastasis formation in vivo [33].
More recently, miR-9 expression was found to be signifi-
cantly increased in paired primary tumors and distant
metastatic sites, suggesting direct involvement of miR-9 in
the metastatic process [34,35]. In concordance with the
potential role of miR-9 in malignant mast cell behavior,
the BR and C2 canine malignant cell lines expressed high
levels of miR-9 compared to normal canine BMMCs.
Taken together, these data support the notion that dysreg-
ulation of miR-9 may contribute to the aggressive biologic
behavior of some canine MCTs.
While activating KIT mutations clearly contribute to
the malignant behavior of mast cells, additional cooper-
ating or initiating genetic defects may be required for
the malignant transformation and promotion of the
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http://www.biomedcentral.com/1471-2407/14/84metastatic phenotype [3]. Our data demonstrate that
overexpression of miR-9 in the C57 and P815 mouse
malignant mast cell lines and normal mouse BMMCs
significantly enhanced the invasive behavior of mast cells
and indicate that miR-9 induces a pattern of gene dys-
function associated with an invasive phenotype regardless
of KIT mutation status.
While some studies have shown that miR-9 promotes
metastasis formation [33,36-39] other contrasting studies
suggest that increased expression of miR-9 suppresses me-
tastasis formation [40,41] and that miR-9 inhibits tumor
growth [42]. The opposing roles of miR-9 in various tis-
sues may be explained by the expression of different
mRNA targets in distinct cellular and developmental con-
texts. Indeed, miRNA effects do appear to be cell type/
tissue specific and contextual in nature. Previous studies
have demonstrated that miR-9 is overexpressed in CDX2-
negative primary gastric cancers and miR-9 knockdown
inhibits proliferation of human gastric cancer cell lines
[43]. In contrast, miR-9 is downregulated in human ovar-
ian tumor cells and overexpression of miR-9 suppresses
their proliferation, in part by downregulating NFκB1
[40,42]. Moreover, miRNA dysregulation may affect only
certain aspects of cell behavior. In our studies, miR-9 ex-
pression in mast cell lines did not provide a survival advan-
tage or prevent apoptosis, but it did alter the invasive
phenotype, supporting the contextual nature of miR-9 in-
duced effects.
To gain insight into possible mechanisms underlying
the observed miR-9-dependent invasive behavior of mast
cells, we evaluated the effects of miR-9 expression on
the transcriptional profiles of BMMCs and P815 cells.
MiR-9 modulated the expression of a large number of
gene transcripts, including down-regulation of several
putative miR-9 targets identified by computational pre-
diction programs. Furthermore, down-regulation of per-
oxisome proliferator-activated receptor δ (PPARG) was
observed in BMMCs following enforced miR-9 ex-
pression, a finding consistent with recent studies demon-
strating that regulation of PPARG expression is mediated
by miR-9 through direct targeting of its 3’-UTR [25]. To
draw firm conclusions regarding direct regulation of target
gene expression by miR-9, a functional approach for each
gene would be required to validate whether these genes are
true miR-9 targets, which although relevant, was outside
the scope of this study.
Overexpression of miR-9 significantly altered gene ex-
pression in both BMMCs and P815 cells, however, most
gene transcripts affected by miR-9 expression differed
between normal and malignant mast cells. These ob-
served differences likely reflect variations in the impact
of miR-9 that are dependent on cellular context. In our
study, we identified gene transcripts that showed similar
changes in expression following miR-9 overexpression inboth normal and malignant mast cells and validated sev-
eral genes demonstrating significant changes in expres-
sion (interferon-induced transmembrane protein protein
3, IFITM3; PDZK1 interacting protein 1, PDZK1IP1) or
implicated in promoting the metastatic phenotype (mast
cell chymase, CMA1). IFITM3 belongs to a family of
interferon-induced transmembrane proteins that con-
tribute to diverse biological processes, such as antiviral
immunity, germ cell homing and maturation, and bone
mineralization. The function of these proteins in mast
cells is currently unclear [44]. PDZK1IP1 is a small, non-
gycosylated membrane-associated protein that localizes
to the plasma membrane and Golgi apparatus. While the
function of PDZK1IP1 has not been evaluated in mast
cells, overexpression of PDZK1IP1 has been documented
in human ovarian, breast, and prostate carcinomas and
this strongly correlates with tumor progression [45,46].
Furthermore, overexpression of PDKZK1IP1 in melanoma
cell lines enhances cell proliferation, decreases apoptosis,
increases cell migration and is, in part, mediated by an in-
crease in reactive oxygen species (ROS) production [47].
Chymases are serine proteases possessing chymotrypsin-
like activity expressed exclusively by mast cells that
promote matrix destruction, tissue remodeling and modu-
lation of immune responses by hydrolyzing chemokines
and cytokines [48]. Given the role of chymase in the
activation of matrix metalloproteases and extracellular
matrix degradation, our findings suggest that miR-9 en-
hances invasion, in part, through increased expression
chymase. Indeed, miR-9 overexpression in normal mast
cells resulted in increased expression of CMA1 with a
concomitant decrease in the expression of secretory
leukocyte peptidase inhibitor (SLPI), a direct inhibitor of
chymase [49]. These findings are consistent with the no-
tion that that miR-9 promotes a pattern of gene expres-
sion contributing to enhanced invasion and suggests a
role for chymase in mediating the biologic functions of
miR-9.
Interestingly, miR-9 modulated the expression of other
proteases in normal mast cells, including up-regulation
of heparinase (HSPE). Heparinase is an endogylocosidase
that functions in the degradation and release of heparan
sulfate-bound growth factors [50]. Previous studies have
shown that enzymatic cleavage of heparin sulfate by
heparinase results in disassembly of the extracellular
matrix and basement membrane dissolution, inducing
structural modifications that loosen the extracellular
matrix barrier and enable cell invasion [51]. Heparinase
increases tumor invasion in both cell lines and spontan-
eous tumor models, through both extracellular matrix
remodeling and increased peritumoral lymphangio-
genesis [52]. Our data show that normal mast cells
overexpressing miR-9 exhibit markedly increased HSPE
expression, supporting the assertion that miR-9 may
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http://www.biomedcentral.com/1471-2407/14/84promote the metastatic phenotype by enhancing the
proteolytic activity of a number of proteases important
in physical remodeling of the extracellular matrix and
activate mediators responsible for cell dissemination.
The present study investigated alterations in gene
transcript expression affected by miR-9; however, these
changes were not demonstrated at the protein level.
Gene expression does not directly correlate with changes
at the protein level and miRNAs may suppress protein
expression by post-transcriptional silencing mechanisms
that are not reflected in transcriptional profiling ana-
lyses. Furthermore, inhibition of miR-9 in canine mast
cell lines would provide further convincing evidence of
its importance in mast cell invasion. As such, identifying
proteins altered by miR-9 that promote cell invasion and
validating these targets in canine cell lines/tumors repre-
sents an area of ongoing investigation.
Conclusion
In summary, the work presented here is the first to dem-
onstrate that unique miRNA expression profiles cor-
relate with the biological behavior of canine MCTs.
Furthermore, overexpression of miR-9 is associated with
aggressive biologic behavior of canine MCTs, possibly
through the promotion of a metastatic phenotype as
demonstrated by enhanced invasive behavior of normal
and malignant mast cells and alteration of gene expres-
sion profiles associated with cellular invasion in the pres-
ence of enforced miR-9 expression. Future work to
dissect the exact mechanisms through which miR-9 ex-
erts the invasive phenotype is ongoing with the ultimate
goal of identifying potential druggable targets for thera-
peutic intervention.
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